GLPBio

PROTAC CARM1 degrader-1 TFA

Catalog No.: GC81882Purity:>98.00%
PROTAC CARM1 degrader-1 TFA is a highly selective CARM1 PROTAC degrader, with a DC50 of 8.1 nM in MCF‑7 cells.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.


PROTAC CARM1 degrader-1 TFA
500μgIn Stock
$468.00
1

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

PROTAC CARM1 degrader-1 TFA is a highly selective CARM1 PROTAC degrader, with a DC50 of 8.1 nM in MCF‑7 cells. PROTAC CARM1 degrader-1 TFA recruits the VHL E3 ubiquitin ligase complex to act on CARM1, inducing a proteasome-dependent degradation process. PROTAC CARM1 degrader-1 TFA downregulates the methylation level of CARM1 substrates in breast cancer cells, inhibits breast cancer cell migration, and exhibits no significant inhibitory effect on cell proliferation. PROTAC CARM1 degrader-1 TFA is applicable for related research on breast cancer [1]. (Pink: CARM1 ligand; Blue: VHL ligand; Black: linker).

In Vitro, PROTAC CARM1 degrader-1 (Compound 3b) (0.01‑500 nM; 24 h) TFA potently induces the degradation of CARM1 protein in MCF‑7 cells (DC50 = 8.1 nM, Dmax = 97%), and exhibits high selectivity over PRMT1, PRMT5, and PRMT6; moreover, the CARM1 degradation activity is abolished upon co-treatment with MG132, MLN4924, VH-032 or TP-064 [1]. PROTAC CARM1 degrader-1 (0.5 μM; 48 h) TFA downregulates the asymmetric dimethylation modification of the CARM1 substrates BAF155 and PABP1 in MCF‑7 cells[1]. PROTAC CARM1 degrader-1 (0.5 μM; 20 h) TFA exerts a significant migration inhibitory effect on MDA-MB-231 triple-negative breast cancer cells, with no apparent anti-proliferative activity[1].

References:
[1]. Xie H, et al. Development of Potent and Selective Coactivator-Associated Arginine Methyltransferase 1 (CARM1) Degraders. Journal of medicinal chemistry. 2023 Sep 28;66(18):13028-13042.

Produktdokumente (Product Documents)

Purity:>98.00%Appearance:A solid

Chemische Eigenschaften (Chemical Properties)

Summenformel
C73H99F3N12O10S
Molekulargewicht
1393.7
Löslichkeit
DMSO: 100 mg/mL (71.75 mM; Need ultrasonic)
Lagerung
Store at 4°C, sealed storage, away from moisture and light
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for PROTAC CARM1 degrader-1 TFA

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%